Khoury Aleen, Deo Krishant M, Aldrich-Wright Janice R
School of Science, Western Sydney University, Campbelltown, NSW 2560, Australia.
School of Science, Western Sydney University, Campbelltown, NSW 2560, Australia.
J Inorg Biochem. 2020 Jun;207:111070. doi: 10.1016/j.jinorgbio.2020.111070. Epub 2020 Mar 23.
Current platinum-based drugs used in chemotherapy, like cisplatin and its derivatives, are greatly limited due to side-effects and drug resistance. This has inspired the search for novel platinum-based drugs that deviate from the conventional mechanism of action seen with current chemotherapeutics. This review highlights recent advances in platinum(II) and platinum(IV)-based complexes that have been developed within the past six years. The platinum compounds explored within this review are those that display a more targeted approach by incorporating ligands that act on selected cellular targets within cancer cells. This includes mitochondria, overexpressed receptors or proteins and enzymes that contribute to cancer cell proliferation. These types of platinum compounds have shown significant improvements in anticancer activity and as such, this review highlights the importance of pursuing these new designed platinum drugs for cancer therapy, with the potential of undergoing clinical trials.
目前化疗中使用的铂类药物，如顺铂及其衍生物，由于副作用和耐药性而受到极大限制。这激发了人们对新型铂类药物的探索，这些药物偏离了当前化疗药物的传统作用机制。本综述重点介绍了过去六年中开发的基于铂（II）和铂（IV）的配合物的最新进展。本综述中探讨的铂化合物是那些通过结合作用于癌细胞内选定细胞靶点的配体而表现出更具靶向性方法的化合物。这包括线粒体、过度表达的受体或蛋白质以及促进癌细胞增殖的酶。这些类型的铂化合物在抗癌活性方面已显示出显著改善，因此，本综述强调了研发这些新设计的铂类抗癌药物的重要性，它们有可能进入临床试验阶段。
